{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-103543","form_type":"8-K","ticker":"LNTH","cik":"0001521036","company_name":"Lantheus Holdings, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.209521+00:00","generated_at":"2026-05-17T19:18:17.669883+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lantheus Q2 rev $378M, adj EPS $1.57; cuts FY25 guidance; FDA NDA acceptance; $400M buyback","bullets":["Q2 revenue $378.0M (-4.1% YoY); GAAP EPS $1.12; adjusted EPS $1.57.","PYLARIFY sales $250.6M (-8.3%); DEFINITY sales $83.9M (+7.5%).","FY25 revenue guidance cut to $1.475-$1.51B from $1.55-$1.585B; adj EPS to $5.50-$5.70 from $6.60-$6.70.","FDA accepted NDA for new piflufolastat F 18 formulation; PDUFA date March 6, 2026; batch size +~50%.","Board authorized $400M share repurchase program through Dec 2027, replacing prior $400M program."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-103543","json":"https://secwatch.observer/filing/0000950170-25-103543.json","markdown":"https://secwatch.observer/filing/0000950170-25-103543.md","text":"https://secwatch.observer/filing/0000950170-25-103543.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1521036/000095017025103543/0000950170-25-103543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1521036/000095017025103543/lnth-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:18:17.669883+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}